BUSINESS MODEL DEVELOPMENT FOR ORPHAN DRUG BUSINESS IN INDONESIA (CASE STUDY: IDIOPATHIC PULMONARY FIBROSIS DRUG)
Over past 25 years, drug research and development was focus to discover treatment for debilitating diseases with high prevalence. Nowadays, many innovative global pharmaceutical companies interest and start to invest their budget and resources to discover new drugs taking a targeted approach to atta...
Saved in:
Main Author: | Ria Veronica, Donda |
---|---|
Format: | Theses |
Language: | Indonesia |
Online Access: | https://digilib.itb.ac.id/gdl/view/35809 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Institut Teknologi Bandung |
Language: | Indonesia |
Similar Items
-
The Perils and Pitfalls of Esophageal Dysmotility in Idiopathic Pulmonary Fibrosis
by: Ramsah Cheah, et al.
Published: (2022) -
Genome-wide association study of susceptibility to idiopathic pulmonary fibrosis
by: Richard J. Allen, et al.
Published: (2020) -
Short-term outcomes of lung transplant in idiopathic pulmonary fibrosis
by: Teo, A.Tk., et al.
Published: (2014) -
Patent Rights & International Public Health: Orphan Drugs
by: HEATHER ANGELINE ROBERTSON
Published: (2010) -
Risk of venous thromboembolism in patients with idiopathic pulmonary fibrosis: A systematic review and meta-analysis
by: Boonphiphop Boonpheng, et al.
Published: (2019)